Bristol-Myers Squibb BMY Opdualag — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's opdualag — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's opdualag — total revenues?
- Bristol-Myers Squibb (BMY) reported opdualag — total revenues of $349M in Q2 2026.
- How has Bristol-Myers Squibb's opdualag — total revenues changed year-over-year?
- Bristol-Myers Squibb's opdualag — total revenues increased by 22.9% year-over-year, from $284M to $349M.
- What does opdualag — total revenues mean?
- This metric represents the total global net sales generated from the commercialization of Opdualag, a fixed-dose combination therapy used primarily in the treatment of advanced melanoma. As a key asset in the company's immuno-oncology portfolio, this revenue stream reflects the market adoption and clinical penetration of the product within the competitive oncology landscape. Monitoring these revenues provides insight into the company's ability to successfully launch and scale novel combination therapies to drive long-term growth.